ImmunoPrecise Antibodies

What ImmunoPrecise Antibodies does

ImmunoPrecise Antibodies Ltd., now operating as MindWalk Holdings Corp. (NASDAQ: HYFT), is a Canada-based, publicly traded biotech company that provides antibody discovery and development services to pharmaceutical and biotechnology clients. The company has built a Bio-Native AI platform called LensAI, powered by its proprietary HYFT technology that structures more than 25 billion biological relationships into a traceable knowledge graph spanning targets, sequences, structures, functions, and literature. This AI layer is paired with advanced wet lab research capabilities, including the B Cell Select platform for antibody identification, Rapid Prime immunization, in silico epitope mapping, and protein engineering, forming an integrated offering branded as the BioIntelligence Ecosystem. The platform has supported 20+ client molecules advanced to clinical trials, including Acumen Pharmaceuticals' sabirnetug (Phase 2) and OncoResponse's immunoinhibitory receptor candidates (Phase I/II).

The company operates a B2B services and partnership model targeting large pharma and biotech clients across therapeutic antibodies, anti-drug antibodies, diagnostics, peptide therapeutics, and vaccines. Revenue mechanics blend professional services on custom engagements with a newer LensAI SaaS self-service offering and pre-built biologics pipeline assets marketed through "The Vault." Named partnerships include Genmab, Janssen Pharma, NIH, Novo Nordisk, Argenx, and MJ Fox Foundation, alongside case-study customers such as GentiBio and Amyl Therapeutics. The company maintains a headcount of 51–100 employees and has executed multiple acquisitions (U-Protein Express 2017, ModiQuest 2018, BioStrand 2022, Carterra LSA 2024) to expand both wet lab and AI capabilities. Following its repositioning under the MindWalk brand, the company regained Nasdaq minimum bid price compliance in July 2025 and continues to broaden its platform with products such as ReefIQ, a biological context layer for AI drug discovery.

Name

ImmunoPrecise Antibodies

Legal name

ImmunoPrecise Antibodies Ltd.

Website

https://ipatherapeutics.com

Company type

Public

Founded year

1983

Operating status

Operating

Headcount range

51–100 employees

Short description

ImmunoPrecise Antibodies, now MindWalk Holdings Corp. (NASDAQ: HYFT), is a Canada-based AI-driven biotech providing antibody discovery and development services to pharmaceutical and biotechnology clients via its Bio-Native LensAI platform, HYFT knowledge graph, and B Cell Select laboratory capabilities.

Ownership category

akta.pro rank

Product category

Antibody Discovery & Biologics CRO Services

NAICS

Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• Antibody discovery services
• Bio-Native AI platform
• Biological knowledge graph
• Biologics discovery CRO
• Computational epitope mapping

Headquarters

HQ city

Victoria

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biologics Discovery Services: The company provides antibody discovery and development services to pharmaceutical and biotech companies through strategic partnerships. Services include therapeutic antibody discovery, anti-drug antibody discovery, diagnostic antibody discovery, and protein engineering and production.
2. LensAI SaaS Platform: Cloud-based AI platform for antibody discovery and biological analysis available as software-as-a-service to clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ImmunoPrecise Antibodies operates an integrated BioIntelligence Ecosystem that combines Bio-Native AI (LensAI/HYFT) with advanced wet-lab antibody discovery services to deliver therapeutic antibodies, anti-drug antibodies, diagnostic antibodies, peptide therapeutics, and vaccine candidates to pharmaceutical and biotechnology clients. Its sellable offerings include the LensAI SaaS platform, the B Cell Select antibody discovery platform, Rapid Prime Immunization lab services, epitope mapping, and The Vault of partner-ready biologics pipeline assets. The company engages clients through 1:1 strategic partnerships and self-service SaaS access, supporting programs from target identification through clinical candidate advancement.

Product overview

MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) operates a unified hybrid platform called the BioIntelligence Ecosystem, integrating Bio-Native AI tools — specifically LensAI powered by HYFT technology — with advanced wet lab research services for antibody discovery and development. The core product portfolio includes LensAI (the AI reasoning engine), HYFT (the biological knowledge graph with 25+ billion relationships), B Cell Select (antibody discovery platform with AI integration), and LensAI SaaS (self-service cloud access). Supporting capabilities span Rapid Prime Immunization (accelerated immunization method), epitope mapping (computational analysis service), and The Vault (partner-ready biologics pipeline assets). The platform is configured for therapeutic antibodies, anti-ID/anti-drug antibodies, diagnostics, peptide therapeutics, and vaccine programs, with a dedicated scientific team providing 1:1 program support.

Differentiator

Problem solved

Functional benefit

Brands

• LensAI: AI-powered antibody discovery platform that links sequence, structure, function, and literature to generate biological insight.
• HYFT
• B Cell Select

Products and services

• LensAI Bio-Native AI platform that links sequence, structure, function, and literature to generate explainable, traceable biological insights, supporting antibody discovery, epitope mapping, and complex biological systems for pharma and biotech clients.
• HYFT Biological data infrastructure that maps more than 25 billion biological relationships into a structured, traceable knowledge graph, converting fragmented biological data into explainable connections across targets, sequences, and functions, and powering LensAI and downstream discovery workflows.
• LensAI SaaS Self-service cloud-based access to the LensAI platform, enabling external researchers and partners to leverage Bio-Native AI capabilities for their own biologics discovery programs as a SaaS subscription.
• B Cell Select Platform Advanced antibody discovery platform for the identification and selection of B cells producing high-value antibody candidates, integrated with LENSai AI for rabbit antibody platforms and used to generate specific binders against targets in autoimmunity, inflammation, and oncology.
• Therapeutics Discovery Services End-to-end antibody discovery and development services for therapeutic antibody programs, supporting clients from target through to clinical candidates including programs with Acumen (sabirnetug, Phase 2), OncoResponse (Phase I/II), and Amyl Therapeutics.
• Anti-Drug Antibody Discovery Service offering focused on the discovery and development of anti-drug and anti-idiotype antibodies for pharmaceutical and biotech clients, integrated with the B Cell Select platform and LENSai.
• Diagnostic Antibody Discovery Antibody discovery services aimed at diagnostic applications, leveraging the B Cell Select platform and AI-enabled screening to identify high-quality diagnostic antibodies for client pipelines.
• Protein Engineering & Production Protein engineering and production services applying LensAI in silico screening, developability analysis, and protein engineering to optimize candidate performance for therapeutic and research programs.
• Rapid Prime Immunization Accelerated immunization method used within MindWalk's advanced lab research workflow to rapidly generate immune responses for antibody discovery; central to clinical candidates including Acumen's sabirnetug.
• Epitope Mapping Computational epitope mapping service powered by LensAI delivering crystallographic-level accuracy predictions, aligning molecular precision with x-ray crystallography validation for antibody-antigen interaction analysis.
• The Vault — Partner-Ready Biologics Pipeline Assets Pre-built, partner-ready biologics pipeline assets made available to external collaborators and partners to accelerate their own antibody discovery and development programs.
• BioIntelligence Ecosystem Integrated discovery platform combining Bio-Native AI (LensAI/HYFT), deep biological data, and advanced wet-lab research to support antibody discovery, peptide therapeutics, and vaccine programs across all development stages for enterprise clients.

Quantifiable outcome

• 20+ client molecules advanced to the clinic
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• GenmabcoreStrategic or Co-development Partner · 1 January 2023Technology partnership targeting infectious disease antibody development. MindWalk and Genmab collaborated on antibody discovery for therapeutic applications.
• Janssen PharmacoreStrategic or Co-development Partner · 1 January 2021Strategic agreement for antibody therapeutics development. Collaboration leveraging MindWalk's discovery platforms for Janssen's pipeline programs.
• NIH (National Institutes of Health)coreStrategic or Co-development Partner · 1 January 2020Collaboration with NIH and Integrated Biotherapeutics to study structural details of antibodies with therapeutic potential to treat or prevent COVID-19.
• Novo NordiskminorStrategic or Co-development PartnerResearch collaboration referenced in scientific publication for antibody therapeutics development. Work published in EMBO Reports.
• ArgenxminorStrategic or Co-development PartnerResearch collaboration referenced in scientific publication for antibody discovery and development.
• MJ Fox FoundationminorStrategic or Co-development PartnerResearch collaboration for neurodegenerative disease antibody therapeutics development, with published work on PubMed.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Recursion Pharmaceuticals: AI-driven drug discovery platform combining wet-lab and computation. Comparable narrative as a tech-bio platform, though Recursion's emphasis is more on small-molecule phenotypic discovery.
• Generate Biomedicines: Generative AI platform for novel protein therapeutics including antibodies. Direct comparable in 'AI-designed biologics' positioning with pharma partnerships.
• Schrödinger: Computational chemistry and biology platform increasingly applied to biologics design. Comparable in 'Bio-Native AI' positioning and SaaS-plus-services model, though stronger in small-molecule heritage.
• Twist Bioscience: DNA synthesis provider with antibody library and discovery offerings. Comparable as an enabling technology platform for synthetic biology and antibody workflows.

Direct peers

• AbCellera Biologics: AI- and single-cell-driven antibody discovery platform serving large pharma partners. Direct competitor in tech-enabled antibody discovery with overlapping customer base and business model.
• Absci: AI-first generative biology company designing de novo antibodies. Directly competes in AI-driven antibody creation and shares the enterprise pharma partnership motion.
• Adimab: Specialized antibody discovery platform offering partnerships with pharma/biotech. Closely comparable service-plus-platform model with similar therapeutic antibody focus.

Broad incumbents

• Charles River Laboratories: Large CRO offering biologics discovery and development services. Overlaps in antibody discovery services, though Charles River is a much broader, established incumbent.
• GenScript ProBio: Global biotech services and CDMO with antibody discovery, protein engineering, and cell therapy offerings. Overlaps with MindWalk's services and B cell-based discovery capabilities.
• Ligand Pharmaceuticals: Diversified drug discovery and royalty business with antibody-related platforms (e.g., OmniAb). Comparable in monetizing antibody discovery technology through partnerships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/immunoprecise
• YouTubeyoutube.com/@mindwalkAI
• LinkedInlinkedin.com/company/mindwalkcorp
• Facebookfacebook.com/ImmunoPreciseAntibodies

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds11 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImmunoPrecise Antibodies